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1. Introduction  
Approximately 90% of cancer-related death is caused by metastasis. The increased motility 
and invasiveness of metastatic tumor cells is reminiscent of events that occur at the 
epithelial-mesenchymal transition (EMT), which is a characteristic that occurs during 
embryonic development, tissue remodeling, wound healing and metastasis. Interestingly, 
EMT is a dynamic process and mainly occurs at the edges of wounds during healing and at 
the invasive fronts of metastatic tumors, which suggest that EMT is influenced by stimuli 
that emanate from the inflammatory microenvironment. The tumor microenvironment 
consists of many kinds of cells including infiltrated inflammatory cells, such as neutrophils, 
lymphocytes, macrophages and myeloid derived suppressor cells (MDSC). These infiltrated 
immune cells secrete cytokines, chemokines and growth factors, such as TNF-ǂ, TGF-ǃ, IL-6, 
fibroblast growth factor (FGF) and epidermal growth factor (EGF). These growth factors 
contribute significantly to the invasive and metastatic traits of cancer cells by inducing EMT. 
Here, we discuss new insights into the molecular pathways and key regulators that link 
inflammatory tumor microenvironment to EMT and metastasis. 
2. Cancer and immunity: Immunity’s roles in tumor suppression and 
promotion 
One of the most challenging questions in immunology is to understand how the immune 
system affects cancer development and progression. In recent years, after a long eclipse, 
different lines of work have lead to a renaissance of the inflammation-cancer connection 
(Balkwill and Mantovani 2001; Coussens and Werb 2002; Mantovani, Allavena et al. 2008). It 
is now believed that the immune system plays a dual role in cancer: on one hand , it can 
function as an extrinsic tumor suppressor (Dighe, Richards et al. 1994; Kaplan, Shankaran et 
al. 1998; Smyth, Thia et al. 2000; Girardi, Oppenheim et al. 2001; Shankaran, Ikeda et al. 2001; 
Street, Trapani et al. 2002) by destroying cancer cells or inhibiting their outgrowth; on the 
other hand, the immune system can also promote tumor progression by establishing 
conditions within the tumor microenvironment that facilitate tumor outgrowth (Schreiber, 
Old et al.). Inflammatory responses play decisive roles at different stages of tumor 
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development, including initiation, promotion, malignant conversion, invasion, and 
metastasis (de Visser, Eichten et al. 2006; Grivennikov, Greten et al. 2010). 
3. EMT and metastasis 
Epithelial-mesenchymal transition (EMT) is a phenotypic conversion during embryonic 
development when tissue remodeling and cell migration shape the future organism, such as 
in embryonic development and wound healing. During EMT, epithelial cells lose the 
adherent junctions that keep them in contact with their neighbors. They gain a mesenchymal 
cell phenotype that enables them to break through the basal membrane and migrate over a 
long distance, a result of profound changes in their cytoskeleton architecture and gene 
expression profile (Kalluri and Neilson 2003). This concept was pioneered by the seminal 
study from Elizabeth Hay using chick primitive streak formation as a model in 1967 (Hay 
1995). Hay realized that an epithelial phenotypic conversion was of crucial importance 
during gastrulation and cell migration in the early vertebrate embryo. She proposed that 
differentiated epithelial cells could undergo a dramatic "transformation" into mesenchymal 
cells (Greenburg and Hay 1988; Hay 1995). However, this "transformation" is reversible: 
mesenchymal cells can revert back to epithelial cells through a reverse process called 
mesenchymal-epithelial transition (MET). As a result, the term “transition” is now used. 
EMT does not only occur during embryonic development or as a physiological response to 
injury. It is also an important element in cancer progression and other pathologies that 
involve organ degeneration, such as fibrosis. At the cellular level, pathological EMTs are 
very similar to physiological EMTs in that they are governed by similar signaling pathways, 
regulators, and effective molecules. 
From a clinical perspective, metastasis is the most critical aspect of tumorigenesis: we have 
already addressed that more than 90% of cancer mortality is caused by metastasis. Aberrant 
control of epithelial proliferation and angiogenesis underlie the initiation and growth of 
primary carcinomas (Hanahan and Weinberg 2011). However, additional steps must be 
completed before a metastatic tumor is successfully established. The spread of malignant 
cells consists of a series of steps, all of which are thought to be important for metastatic 
outgrowth in different organs. Basically, these steps include local invasion toward and entry 
into blood vasculature (intravasation), survival within the circulation system, arrest in 
distant capillary beds or “homing” to distal organs, exit from blood vasculature 
(extravasation), and eventual outgrowth and re-establishment of malignant growths in 
secondary locations (Woodhouse, Chuaqui et al. 1997; Chambers, Naumov et al. 2001; Fidler 
2003; Hanahan and Weinberg 2011). 
3.1 Classification of EMT into three different subtypes 
Based on recent intensive study in this field, EMT can be divided into three subtypes, which 
have different biological functional consequences (Kalluri 2009; Kalluri and Weinberg 2009; 
Zeisberg and Neilson 2009). Type 1 EMT occurs during implantation, embryo formation, 
gastrulation, and neural crest migration, which describes the transition of epithelial cells to 
generate diverse mesenchymal cell types. These primary mesenchymal cells can revert back 
to form secondary epithelia in mesodermal and endodermal organs through MET. Type 2 
EMT occurs during wound healing, tissue regeneration and organ fibrosis, which is usually 
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associated with injury and chronic inflammation. Type 2 EMT ceases once inflammation is 
attenuated, but if inflammation persists, this type of EMT will eventually lead to tissue 
fibrosis and organ destruction. Unlike Type 1 EMT, these mesenchymal cells have no 
potential to undergo MET and turn back to epithelial cells. Type 3 EMT occurs during tumor 
progression, which describes how neoplastic cells at the invasive front of primary tumors 
undergo a transition to acquire increased motility and invasive ability, enabling them to 
invade and metastasize through the blood stream or lymph node system, eventually 
generating life-threatening metastatic lesions at distant organs. 
Because studies of EMT often involve various model systems ranging from different 
epithelial cell types to assorted stimulations, it is important to use validated biomarkers to 
examine the phenotypic conversion during all three classes of EMT. Common biomarkers 
include cell-surface and extracellular molecules, cytoskeletal proteins and specific 
transcription factors. For example, down-regulation of E-cadherin is a hallmark of EMT, and 
loss of E-cadherin expression facilitates the induction of EMT (Huber, Kraut et al. 2005). E-
cadherin is a cell-cell adhesion molecule that participates in homotypic, calcium-dependent 
interactions to form epithelial adherent junctions (Cowin, Rowlands et al. 2005; Junghans, 
Haas et al. 2005). In addition, E-cadherin repressors, such as Snail, Slug, Twist and ZEB1/2, 
are commonly used as EMT markers. Snail is the first described E-cadherin repressor and is 
also the common downstream target of various signaling pathways that lead to EMT. 
Vimentin, an intermediate filament mainly expressed in fibroblasts, endothelial cells and 
hematopoietic cells, is also commonly used as an indicator for Type 3 EMT, since expression 
of vimentin in tumor cells correlates with their invasiveness and metastatic potential. 
Furthermore, differential expression of integrin is also used as a biomarker of EMT, since 
integrins modulate the interaction of cells with extracellular matrix (ECM). For example, 
increased expression of ǂ5 integrin is commonly found in Type 2 and Type 3 EMT (Qian, 
Zhang et al. 2005; Davidson, Marsden et al. 2006; White, Blanchette et al. 2007). 
3.2 Type1 EMT in the formation of mesoderm and neural crest 
EMT is crucially important to tissue morphogenetic events during embryonic development, 
such as the mesoderm formation, neural crest formation, heart valve development, and 
secondary palate formation. Without EMT, development cannot proceed through the 
blastula stage. Mesoderm formation and neural crest development represent the major EMT 
programs that occur during early embryonic development; the resulting mesenchymal and 
neural crest cells act as progenitors and further differentiate into various cell types via MET. 
For example, gastrulation EMT produces the mesoderm, giving rise to muscle, bone and 
connective tissues, whereas neural crest delamination EMT gives rise to glial and neuronal 
cells, adrenal glandular tissues, pigment-containing cells of the epidermis and skeletal and 
connective tissues. The heart valve development and secondary palate formation occur in 
relatively well-differentiated epithelial cells that are destined to become defined 
mesenchymal cells types.  
The formation of mesoderm from the primitive ectoderm during gastrulation is the classic 
example of EMT. Gastrulation, observed in all metazoans, is accompanied by drastic 
morphogenic changes from a single epithelial layer (the epiblast) into three embryonic germ 
layers, the ectoderm, mesoderm, and endoderm, to form a complex three-dimensional 
multilayered embryo (Shook and Keller 2003). In chicken and mouse embryo, Wnt and TGF-
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ǃ signaling provide the initial induction signals for EMT, while the FGF signal is necessary 
to maintain the EMT regulatory network during mesoderm formation. All these signaling 
events activate the expression of Snail, which represses the expression of E-cadherin and 
other tight junction components (such as claudins, occludins, and Crumbs) and promotes 
cell migration. In Snail knock-out mice the cells that form are unable to migrate, although 
mesoderm specification is not affected.  
Neural crest formation is another example of Type 1 EMT in embryogenesis where 
premigratory neural crest cells form at the border of the neural plate and non-neural 
ectoderm as a result of signals emanating from these two tissues. Interestingly, similar 
signaling pathways operating during EMT at gastrulation are used in the neural crest 
formation. Indeed, a combination of Wnt, FGF, and TGF-ǃ (mainly BMP) induce the 
expression of Snail, Sox and forkhead box D3 transcription factors (Villanueva, Glavic et al. 
2002). In addition, experimental evidence shows that Notch signalling pathway plays an 
important role in neural crest formation through induction of Slug in frog and chick embryo 
(Nieto 2002). The combination of these transcription factors generates the full spectrum of 
phenotypic changes associated with EMT and primes the precursor cells to become 
migratory neural crest cells. These neural crest cells are equipped with the ability to migrate 
over extraordinarily long distances in the embryo, prior to their reaggregation via MET for 
further differentiation. 
3.3 Type 2 EMT in tissue and organ fibrosis 
3.3.1 Implications of EMT in fibrosis 
Re-epithelization, tissue regeneration and organ fibrosis constitute Type 2 EMT. Organ 
fibrosis is mediated by inflammatory cells and fibroblasts, which deposit collagens, elastin, 
tenacin and other matrix molecules. Fibrosis-associated Type 2 EMT specifically occurs in 
kidney, liver, lung and intestine (Zeisberg, Tarnavski et al. 2007). A series of typical 
experiments has shown that EMT is an important process during tissue injury that leads to 
organ fibrosis. In terms of EMT proteomes, fibroblast-specific protein 1 (FSP1, also known 
S100A4 and MTS-1), ǂ-SMA (smooth muscle actin) and collagen I are reliable markers to 
characterize the mesenchymal products generated by EMTs in the development of fibrosis 
in various organs. TGF-ǃ1, as the major pro-fibrotic cytokine, induces many of the central 
processes involved in fibrosis, including differentiation of fibroblast to myfibroblasat, ECM 
deposition and EMT. TGF-ǃ not only contributes to pulmonary and hepatic fibrosis, but also 
plays a key role in cardiac fibrosis (Gressner, Weiskirchen et al. 2002; Willis and Borok 2007; 
Zeisberg, Tarnavski et al. 2007). TGF-ǃ induces EMT via both a Smad2/3-dependent 
pathway and a MAPK-dependent pathway. The relevance of TGF-ǃ-induced EMT for 
progression of organ fibrosis was recently further elucidated using BMP-7 as an intracellular 
competitor of TGF-ǃ signaling in mouse models of kidney, liver, billiard tract, lung and 
intestinal fibrosis (Zeisberg, Bottiglio et al. 2003; Zeisberg, Hanai et al. 2003). The function of 
TGF-ǃ in fibrosis is highlighted by the finding that Smad3-/- mice are resistant to the 
induction of several fibrotic diseases (Flanders 2004). TGF-ǃ levels are also over-produced 
and are associated with functional impairment in patients with fibrotic pulmonary diseases 
such as idiopathic pulmonary fibrosis (Salez, Gosset et al. 1998). Clinical studies have also 
demonstrated the correlation between fibrosis and EMT (Rastaldi, Ferrario et al. 2002). 
Using immunohistochemistry and in situ hybridization, an EMT was demonstrated with the 
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expression of several markers of tubular phenotype transition, such as cytokeratin, 
vimentin, ǂ-SMA and zona occludens (ZO-1) in 133 kidney biopsies (Rastaldi, Ferrario et al. 
2002). Similarly, an expression pattern of EMT was found in areas of fibrosis in the colon in 
patients with Crohn’s disease (Bataille, Rohrmeier et al. 2008).  
3.3.2 Re-epithelialization of wounded skin 
Re-epithelialization recapitulates several aspects of EMT. Re-epithelialization requires 
epithelial cells at the edge of wounded tissue to loosen their cell–-cell and cell–-ECM 
contacts and assume a migratory phenotype, reminiscent of EMT. Slug has a crucial role in 
wound-healing, which is expressed in keratinocytes at the boundary of wounds. 
Importantly, epithelial cell outgrowth from skin explants was markedly reduced in Slug 
knockout mice, whereas overexpression of Slug in cultured human keratinocytes result in 
increased cell spreading and desmosomal disruption (Savagner, Kusewitt et al. 2005). 
Arnoux et al further found that EGF can activate Erk5, which specifically enhances Slug 
promoter activity and controls wound healing in keratinocyte-derived HacaT cells in vitro 
(Arnoux, Nassour et al. 2008). However, it should be noted that not all features of EMT are 
seen. First, the migrating keratinocytes remain part of a cohesive cell sheet since they retain 
some intercellular junction. Second, the epithelial cells do not actually become mesenchymal 
(i.e., interstitial) cells. They retain epithelial characteristics. Once wound closure is complete, 
the involved epithelial cells revert to their tissue-specific, differentiated state. 
3.4 Type 3 EMT in cancer metastasis 
Cancer metastasis is believed to consist of four distinct steps: invasion, intravasation, 
extravasation and metastatic colonization (Chambers, Groom et al. 2002; Pantel and 
Brakenhoff 2004). During invasion, tumor cells lose cell-cell adhesion, gain mobility and 
leave the site of the primary tumor to invade adjacent tissues. In intravasation, tumor cells 
penetrate through the endothelial barrier and enter systemic circulation through blood and 
lymphatic vessels. In extravasation, cells that survive anchorage-independent growth 
conditions in the bloodstream attach to vessels at distant sites and leave the bloodstream. 
Finally, in metastatic colonization, tumor cells form macrometastases in the new host 
environment (Chambers, Groom et al. 2002; Pantel and Brakenhoff 2004). All of these steps, 
from initial breakdown of tissue structure through increased invasiveness, and ultimately 
distribution and colonization throughout the body, are characteristics of the developmental 
process at EMT/MET. The similarity of genetic controls and biochemical mechanisms 
underlying the acquisition of the invasive phenotype, and the subsequent systemic spread 
of the cancer cells, highlights that tumor cells usurp this developmental pathway for their 
metastatic dissemination. We will further discuss this type of EMT, with more detail on how 
it is regulated by different signaling pathways and molecular in various tumor 
microenvironments.   
3.5 Molecular regulation of EMT 
The hallmark of EMT is the loss of E-cadherin expression, an important caretaker of the 
epithelial phenotype. Loss of E-cadherin expression is often correlated with the tumor grade 
and stage, because it results in disruption of the cell-cell adhesion and an increase in nuclear 
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ǃ-catenin (Cowin, Rowlands et al. 2005; Junghans, Haas et al. 2005). Several transcription 
factors have been implicated in the regulation of EMT, including zinc finger proteins of the 
Snail/Slug family, the basic helix-loop-helix factor Twist, E12/E47, Goosecoid, ǅEF1/ZEB1 
and SIP1 (Nieto 2002; Yang, Mani et al. 2004; Hartwell, Muir et al. 2006). These factors act as 
a molecular switch of EMT program by repressing a subset of common genes that encode 
cadherins, claudins, integrins, mucins, plakophilin, occludin and ZO1 to induce EMT. For 
example, Snail expression is associated with E-cadherin repression in metastasis; it also 
correlates with tumor recurrence and poor prognosis in various cancers (Elloul, Elstrand et 
al. 2005; Moody, Perez et al. 2005; Bruyere, Namdarian et al. 2009). In addition, extensive 
crosstalk among these transcription factors forms a signaling network that is responsible for 
establishing and maintaining mesenchymal cell phenotypes. Furthermore, some of these 
transcription factors, including Snail, play an important part in overcoming oncogene-
induced senescence (Ansieau, Bastid et al. 2008), inhibiting tumor immunosuppression 
(Kudo-Saito, Shirako et al. 2009) and generating tumorigenic cancer stem cells (Mani, Guo et 
al. 2008). These transcription factors communicate and respond to extracellular signals such 
as growth factors, cytokines and hypoxia from their microenvironment to induce EMT.  
Many signaling pathways trigger EMT in both embryonic development and in normal and 
transformed cell lines. The signaling pathways include those triggered by different members 
of the TGF-ǃ superfamily, Wnts, Notch, EGF, FGF and many others (Fig.1). 
 
Fig. 1. Overview of the Molecular regulation of EMT. 
TGF-ǃ is a primary inducer of EMT. It not only contributes to EMT during embryonic 
development, but also induces EMT during tumor progression in vivo (Zavadil and Bottinger 
2005). Overexpression of Smad2 and Smad3 result in increased EMT in a mammary epithelial 
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model (Valcourt, Kowanetz et al. 2005). Knockout of Smad3 blocks TGF-ǃ-induced EMT in 
primary tubular epithelial cells; the reduction of Smad2 and Smad3 function is associated with 
the decreased metastatic potential of breast cancer cell lines in a xenograft model (Zavadil, 
Cermak et al. 2004). It is interesting that SMAD3 and SMAD4 interact and form a complex 
with Snail, targeting the promoters of CAR (a tight-junction protein) and E-cadherin during 
TGF-ǃ-inducing EMT in breast epithelial cells (Vincent, Neve et al. 2009). Bos et al identified 
that TGF-ǃ primed cancer cells for lung metastasis through angiopoietin-like 4 via Smad 
signaling pathway (Bos, Zhang et al. 2009). In contrast, inhibition of TGF-ǃ or TGF-ǃ receptor 
reduces the invasive and metastatic activities of cancer cells. TGF-ǃ can also downregulate 
various epithelial molecules, including E-cadherin, ZO-1 and several specific keratins; it also 
upregulates certain mesenchymal proteins such as fibronectin, fibroblast specific protein 1, ǂ-
smooth muscle actin and vimentin. In addition, TGF-ǃ cooperates with numerous kinases such 
as RAS, MAPK, and p38MAP, to promote EMT (Zavadil and Bottinger 2005; Buijs, Henriquez 
et al. 2007). More specifically, p38 MAPK and RhoA mediate an autocrine TGF-ǃ-induced 
EMT in NMuMG mouse mammary epithelial cells (Bhowmick, Ghiassi et al. 2001). ECM 
molecules, such as integrin ǃ1 and Fibulin-5, augment TGF-ǃ-induced EMT in a MAPK-
dependent mechanism (Bhowmick, Ghiassi et al. 2001; Lee, Albig et al. 2008). Constitutive 
activation of Raf enhances the function of TGF-ǃ in inducing EMT via MAPK in MDCK cells 
(Janda, Lehmann et al. 2002). TGF-ǃ also induces EMT through changes in the expression of 
certain cell polarity molecules. For example, TGF-ǃ can induce phosphorylation of Par6, which 
in turn stimulates binding of Par6 to E3 ligase Smurf1. The Par6-Smurf1 complex then 
mediates the localized ubiquitination of RhoA to disrupt tight junctions during EMT 
(Ozdamar, Bose et al. 2005). TGF-ǃ can also downregulate Par3 expression to destroy cell 
polarity (Wang, Nie et al. 2008). It is interesting to note that Abl can inhibit TGF-ǃ-mediated 
EMT in normal and metastatic mammary epithelial cells (MECs) (Allington, Galliher-Beckley 
et al. 2009). Furthermore, TGF-ǃ can cooperate with other oncogenic pathways, such as Notch, 
Wnt/ǃ-catenin and NF-κB, to maintain the mesenchymal phenotype of invasive/metastatic 
tumor cells (Nawshad, Lagamba et al. 2005; Zavadil and Bottinger 2005; Neth, Ries et al. 2007). 
The Wnt/ǃ-catenin pathway has a particularly tight link with EMT (Li, Hively et al. 2000). 
On one hand, ǃ-catenin is an essential component of adherent junctions, where it provides 
the link between E-cadherin and ǂ-catenin and modulates cell-cell adhesion and cell 
migration. On the other hand, ǃ-catenin also functions as a transcription cofactor with T cell 
factor (TCF). Nuclear translocation of ǃ-catenin can activate expression of Slug, thus 
inducing EMT. Expression of ǃ-catenin in oocyte induces a premature EMT in the epiblast, 
concomitant with Snail transcription. Interestingly, Snail is a highly unstable protein and is 
dually regulated by protein stability and cellular location. We showed that GSK-3ǃ binds 
and phosphorylates Snail at two consensus motifs to dually regulate the function of this 
protein: phosphorylation at the first motif regulates its ubiquitination mediated by ǃ-Trcp, 
and phosphorylation at the second motif controls its subcellular localization (Zhou, Deng et 
al. 2004). Thus, Wnt can suppress the activity of GSK-3ǃ, and it stabilizes the protein level of 
Snail and ǃ-catenin to induce EMT and cancer metastasis (Yook, Li et al. 2005; Yook, Li et al. 
2006). Meanwhile, Snail can functionally interact with ǃ-catenin to increase Wnt-dependent 
target gene expression, promoting EMT (Stemmer, de Craene et al. 2008). Increasing 
evidence indicates that Wnt signaling is strongly associated with human basal-like breast 
cancer. Inhibiting Wnt signaling through LRP6 reduces the capacity of cancer cells to self-
renew and colonize in vivo. It also results in the re-expression of breast epithelial markers 
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and repression of EMT transcription factors Slug and Twist (DiMeo, Anderson et al. 2009). 
How the synergistic activation of Snail and ǃ-catenin by the Wnt signaling pathway, 
enhancing EMT and metastasis, remains to be further defined. 
Notch is an evolutionarily conserved signaling pathway that regulates cell fate specification, 
self-renewal and differentiation in embryonic and postnatal tissues. Four Notch (Notch 1−4) 
and five ligands (Jagged1, 2 and Deltalike1, 3, 4) have been identified. Notch signaling is 
normally activated followed by ligand-receptor binding between two neighboring cells. 
Notch undergoes intramembrane cleavage by Ǆ-secretase, and its intracellular domain 
(NICD) is released and translocates to the nucleus to activate gene transcription by 
associating with Mastermind-like 1 (MAM) and histone acetyltransferase p300/CBP. 
Alteration of Notch signaling has been associated with various types of cancer in which 
Notch can act as an oncogene or as a tumor suppressor, depending on the cellular context. 
The first observation that Notch pathway is required for EMT was derived from cardiac 
valve and cushion formation at heart development (Timmerman, Grego-Bessa et al. 2004). 
This implies that Notch, acting through a similar mechanism, induces EMT during tumor 
progression and converts polarized epithelial cells into motile and invasive ones (Grego-
Bessa, Diez et al. 2004). Indeed, overexpression of Jagged1 and Notch1 induces the 
expression of Slug and correlates with poor prognosis in various human cancers (Leong, 
Niessen et al. 2007). Slug is essential for Notch-mediated EMT by repressing E-cadherin 
expression, which results in ǃ-catenin activation and resistance to anoikis. Inhibition of 
Notch signaling in xenografted, Slug-positive/E-cadherin-negative breast tumors promotes 
apoptosis and inhibits tumor growth and metastasis (Leong, Niessen et al. 2007). In 
addition, Notch signaling deploys two distinct mechanisms that act in synergy to control the 
expression of Snail (Sahlgren, Gustafsson et al. 2008). First, Notch directly upregulates Snail 
expression by recruiting the Notch intracellular domain to the Snail promoter. Second, 
Notch potentiates hypoxia-inducible factor 1ǂ (HIF-1ǂ) recruitment to the lysyl oxidase 
(LOX) promoter and elevates the hypoxia-induced upregulation of LOX, which stabilizes 
the Snail protein. Thus, Notch signaling is required to convert the hypoxic stimulus into 
EMT, and it increases the invasiveness of tumor cells. In addition, the Notch signaling 
pathway is involved in the acquisition of EMT phenotype of gemcitabine-resistant (GR) cells 
in pancreatic cancer (Wang, Li et al. 2009). Down-regulation of Notch signaling is associated 
with decreased invasive behavior of GR cells. Moreover, Notch signaling leads to the 
increased expression of vimentin, ZEB1, Slug, Snail, and NF-κB, and it results in EMT. Thus, 
inhibition of Notch signaling by novel therapeutic strategies can be clinically important in 
overcoming drug resistance and EMT phenotype of tumor cells. 
The Hedgehog (Hh) signaling pathway was first identified in a large screen for Drosophila 
genes required for patterning of the early embryo (Hooper and Scott 2005; Jacob and Lum 
2007). The Hh ligands, Sonic-, Desert-, and Indian Hh in vertebrates and Hh in Drosophila, 
are secreted proteins that undergo several posttranslational modifications to gain full 
activity. Key effectors of Hh signaling include zinc-finger proteins of the Gli1-3 transcription 
factors. Hh signaling can initiate cell growth, cell division, lineage specification and axon 
guidance and can also function as a survival factor. Activation of Hh signaling also leads to 
EMT. In mouse epidermal cells or in rat kidney epithelial cells immortalized with 
adenovirus E1A, Gli1 rapidly induces transcription of Snail and promotes EMT (Li, Deng et 
al. 2006; Li, Deng et al. 2007). Targeted expression of Gli1 in the epithelial cells of mammary 
gland of mice induces the expression of Snail, resulting in the disruption of the mammary 
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epithelial network and alveologenesis during pregnancy (Fiaschi, Rozell et al. 2007). In 
addition, Hedgehog signals induce JAG2 up-regulation for Notch-CSL-mediated Snail 
expression; on the other hand, Hedgehog induces TGF-ǃ1 secretion to induce ZEB1 and 
ZEB2 expression through TGF-ǃ and NF-κB pathways. Conversely, blocking Hedgehog 
signaling by inhibitor cyclopamine suppresses pancreatic cancer invasion and metastasis by 
inhibiting EMT (Feldmann, Dhara et al. 2007). The crosstalk between the Hh and EMT also 
presents in human esophageal squamous cell carcinoma (ESCC) (Isohata, Aoyagi et al. 
2009). Hh and EMT signaling genes are co-expressed on the undifferentiated esophageal 
epithelial cells and in most ESCCs. These findings suggest that mesenchymal gene 
expression is maintained or strengthened through Hh signaling in cancer cells. 
3.6 Microenvironmental regulation of EMT/metastasis 
Metastasis is a multi-step process that requires cancer cells to escape from the primary 
tumor, survive in circulation, seed at distant sites and grow. Each of these processes 
involves rate-limiting steps influenced by non-malignant cells of the tumor 
microenvironment (Joyce and Pollard 2009), composed of multiple cell types, such as stroma 
fibroblasts, epithelial cells, and a variety of bone marrow-derived cells (BMDCs) including 
macrophages, myeloid-derived suppressor cells (MDSCs), and so on. In this surrounding 
environment, a variety of stromal cells are recruited to tumors, not only enhance growth of 
the primary tumor, but also to facilitate its metastatic dissemination to distant organs (Tse 
and Kalluri 2007; Lunt, Chaudary et al. 2009). 
Recent work has indicated that EMT is a dynamic process controlled by signals that cells 
receive from their microenvironment. By adopting a mesenchymal phenotype through EMT, 
individual carcinoma cells can infiltrate adjacent tissues, cross endothelial barriers, and 
enter the circulation through blood and lymphatic vessels. Once the tumor cells reach their 
secondary tissues or organs, they no longer encounter the signals they experienced in the 
primary tumor, and they can revert to an epithelial state via a mesenchymal-epithelial 
transition (MET). Consistent with this notion, EMT commonly occurs at the invasive front 
(tumor-stromal boundary) of many invasive carcinomas (Christofori 2006; Franci, Takkunen 
et al. 2006). These observations indicate that EMT is triggered by cellular signals from 
microenvironment. These immune and inflammatory cells secrete cytokines, chemokines, 
and growth factors, which play essential roles for supporting tumor progression and 
metastasis. Because it is analogous with the role of inflammation in mediating wound 
healing, we hypothesize that the migratory and invasive ability of tumor cells at the invasive 
front is initiated and propelled by an inflammatory microenvironment through the 
induction of EMT. 
4. The role of inflammatory cells and cytokines in EMT/metastasis 
4.1 Tumor-Associated Macrophages (TAMs) 
Consistent with our hypothesis, a high content of inflammatory cells, particularly tumor-
associated macrophages, is commonly found at the invasive fronts of advanced carcinoma 
(Condeelis and Pollard 2006). Macrophages are key cells in chronic inflammation. M1 
macrophages are involved in Type 1 reactions and are classically activated by microbial 
products, killing microorganisms and producing reactive oxygen and nitrogen 
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intermediates. In contrast, M2 cells (tumor associated macrophage; TAM) are important 
components of infiltrated leukocytes in most malignant tumors. They are involved in Type 2 
reactions, tune inflammation and adaptive immunity, promote cell proliferation by 
producing growth factors and enhance angiogenesis, tissue remodeling, and repair. 
Macrophage directly influences the behavior and function of tumor cells and has been 
regarded as an “obligate partner for tumor-cell migration, invasion and metastasis” 
(Condeelis and Pollard 2006). Clinical studies indicate a correlation between TAM density 
and poor prognosis (Pollard 2004). For example, in PyMT-induced mammary tumors, 
macrophages are present in the areas of basement membrane breakdown during the 
development of “early-stage” metastatic lesions and systemic depletion of macrophages 
results in reduced formation of lung metastasis (Lin, Nguyen et al. 2001). TAMs produce a 
wide variety of growth factors (such as FGF, HGF, EGF, PDGF and TGF-ǃ and cytokines 
[such as TNFǂ, interleukin-6, interleukin-1, and interferons]) to stimulate the growth, 
motility, and invasiveness of tumor cells. TAMs also produce many proteases, ranging from 
uPA to a variety of matrix metalloproteinases, to degrade the basement membrane in order 
to create a channel for tumor cell invasion. In our recent study, we found that the 
EMT/invasiveness of tumor cells was dramatically enhanced when they were co-cultured 
with macrophages or macrophage-conditioned medium (Wu, Deng et al. 2009). We showed 
that this effect, mainly mediated by the secretion of TNFǂ from macrophages as 
neutralization of TNFǂ by TNFǂ antibody, greatly suppressed macrophage-mediated tumor 
cell invasion and metastasis(Wu, Deng et al. 2009). Consistent with our finding, Hagemann 
et al found that co-culturing macrophages with tumor cells enhanced their invasive ability 
in a manner dependent on TNFǂ and matrix metalloproteinases (MMP)(Hagemann, Wilson 
et al. 2005). Interestingly, expression of Snail in the non-metastatic breast cancer cell lines 
MCF7 and T47D, which contain little endogenous Snail, greatly increased the invasiveness 
of these cells by inflammation, indicating that Snail, through the induction of EMT, is critical 
for mediating inflammation-induced invasion/metastasis of breast cancer cells. Knockdown 
Snail expression significantly inhibited cell migration and invasion induced by 
inflammatory cytokines; it also suppressed inflammation-mediated breast cancer metastasis 
in animal model. Thus, macrophages, the major inflammatory component of the stroma in 
malignancies, facilitate angiogenesis, extracellular matrix breakdown, invasion, and 
metastasis through multiple mechanisms. 
4.2 T-reg cells  
Regulatory T cells (Treg), which include many populations that differ in phenotype, 
cytokine secretion profile and suppressive mechanism (Maloy and Powrie 2001; Shevach 
2002; Wood and Sakaguchi 2003), were reported to interact with tumor cells, promoting 
rather than inhibiting cancer development and progression. High Treg levels have been 
found in peripheral blood, lymph nodes, and tumor specimens from patients with different 
types of cancer (Wang 2008). Treg have been characterized by the constitutive expression of 
Forkhead box P3 (FoxP3), glucocorticoid-induecd THFR family-related receptor (GITR), 
cytotoxic T lymphocyte associated antigen 4 (CTLA-4), and high levels of the alpha chain of 
the IL-2 receptor (CD25). It was found that Treg numbers were significantly higher in 
patients with metastatic cancer compared to healthy donors (Audia, Nicolas et al. 2007; 
Watanabe, Oda et al. 2010). 
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The level of FoxP3, an indicator of Treg activity, might also be an indicator of breast 
tumorigenesis (Gupta, Joshi et al. 2007). It has been demonstrated that high numbers of 
FoxP3-positive Tregs were present in high-grade tumors, increasing the risk of 
relapse/metastasis (Bates, Fox et al. 2006). Interestingly, the FoxP3 transcription factor, 
recently found to be expressed in tumor cells, can regulate a large number of genes. Besides, 
FoxP3 binds to the gene region upstream of the transcriptional start site of CCR7 and 
CXCR4 (Zheng and Rudensky 2007), two chemokine receptors recently reported to play an 
important role in cancer invasion and metastasis (Kodama, Hasengaowa et al. 2007; Pitkin, 
Luangdilok et al. 2007). Thus, FoxP3 expressed in breast cancer cells might influence 
metastasis by modulating the expression of these chemokine receptors or other genes, which 
encode cell surface or secrete molecules that regulate the response of tumor cells to the 
microenvironment (Merlo, Casalini et al. 2009). 
Recently, it has been demonstrated that pulmonary metastasis of breast cancer requires 
recruitment and expansion of Treg that promote escape from host protective immune cells. 
Arya Biragyn’s group reported that the primary role of tBregs (tumor-evoked Bregs) in lung 
metastases of breast cancer in the mouse 4T1 model is to induce TGF-ǃ–dependent 
conversion of FoxP3+ Tregs from resting CD4+ T cells. In the absence of tBregs, 4T1 tumors 
cannot metastasize into the lungs efficiently due to poor Treg conversion, which suggest 
that tBregs must be controlled to interrupt the initiation of a key cancer-induced- 
immunosuppressive event that is critical to support cancer metastasis.(Olkhanud, 
Damdinsuren et al. 2011) 
Tregs were selectively recruited within lymphoid infiltrates and activated by mature 
dendritic cells likely through the recognition of tumor-associated antigen presentation, 
which result in the prevention of effector T cell activation, immune escape, and ultimately, 
tumor progression (Gobert, Treilleux et al. 2009). Treg depletion may become a successful 
anticancer strategy, and Treg manipulation in terms of frequency and functional activity 
should be added to the therapeutic regimen to enhance tumor immunity in humans (Wolf, 
Wolf et al. 2003). 
4.3 Myeloid-Drived Suppressor Cells (MDSC) and others 
Myeloid-derived suppressor cells (MDSC) are present in many cancer patients and mice 
with transplanted or spontaneous tumors (Young and Lathers 1999; Almand, Clark et al. 
2001). MDSC, characterized as CD11b+ Gr-1+ in mice, can be recruited and activated by 
multiple factors, such as VEGF, IL-1ǃ and IL-6, many of which are associated with chronic 
inflammation (Gabrilovich and Nagaraj 2009). Recent studies indicated that these cells also 
have a crucial role in tumor progression. MDSCs can directly incorporate into tumor 
endothelium. They secret many pro-angiogenic factors as well. In addition, they play an 
essential role in cancer invasion and metastasis through inducing the production of matrix 
metalloproteinases (MMPs), chemoattractants and creating a pre-metastatic environment. 
Recruitment of MDSCs further produces pro-inflammatory factors, resulting in the 
amplification of the pro-inflammatory response. MDSCs not only suppress the adaptive 
immune responses but also regulate innate immune responses by modulating the cytokine 
production of macrophages (Sinha, Clements et al. 2007), thus directly facilitating 
metastasis. Recent studies have shown a close correlation between the level of MDSCs and 
cancer stage, metastatic tumor burden, and responsiveness to chemotherapy (Diaz-Montero, 
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Salem et al. 2009). MDSCs from mammary carcinoma can promote tumor invasion and 
metastasis (Bunt, Yang et al. 2007). In Tgfbr2-decificent mice, MDSCs are concentrated at the 
invasive tumor front and facilitate tumor cell invasion and metastasis through chemokine 
receptors CXCR2 and CXCR4 (Yang, Huang et al. 2008). It has been recently found that 
MDSCs accumulated in pregnant mice and exerted an inhibitory effect on NK cell activity, 
and decreased NK cell activity is responsible for the observed increase in metastasis during 
murine gestation, providing a candidate mechanism for the enhanced metastatic tumor 
growth observed in gestant mice.(Mauti, Le Bitoux et al. 2011) 
In addition to macrophages and MDSC, fibroblasts/myofibroblasts comprise another major 
component of tumor stroma. These cancer-associated fibroblasts (CAF) share a lot of 
characteristics with activated fibroblasts in wound healing and promote tumor progression. 
Recent studies have demonstrated that CAF are important in tumor cell migration and 
metastasis. CAF isolated from metastatic breast cancer produce elevated levels of IL-6 and 
enhance cancer cell invasiveness (Studebaker, Storci et al. 2008). Similarly, De Wever et al 
found that the invasive growth of breast and colon cancer cells could be stimulated using 
myofibroblasts isolated from surgical colon cancer specimens (De Wever, Westbroek et al. 
2004). In addition, CAF in pancreatic ductal adenocarcinoma are responsible for a poorly 
vascularized architecture that imposes a barrier for drug delivery and spurs metastasis 
(Olive, Jacobetz et al. 2009). Furthermore, fibroblasts promote tumor cell proliferation and 
metastasis through the production of several growth factors, cytokines, chemokines, and 
matrix metalloproteinases (MMPs). MMPs derived from tumor cells and stromal 
components are regarded as major players in assisting the metastasis of tumor cells. For 
example, transgenic expression of MMP3 stimulates expression of Snail through the 
increased cellular reactive oxygen species, inducing down-regulation of E-cadherin and 
increased tumor progression (Radisky, Levy et al. 2005). Besides, Reisfeld’s group 
demonstrated recently that CAF are key modulators of immune polarization in the tumor 
microenvironment of a 4T1 murine model of metastatic breast cancer. Elimination of CAF in 
vivo by a DNA vaccine targeted to fibroblast activation protein results in a shift of the 
immune microenvironment from a Th2 to Th1 polarization. This shift is characterized by 
increased protein expression of IL-2 and IL-7, suppressed recruitment of tumor-associated 
macrophages, myeloid derived suppressor cells, T regulatory cells, and decreased tumor 
angiogenesis and lymphangiogenesis. (Liao, Luo et al. 2009) 
Neutrophils are also noted as important cells in the tumor inflammatory microenvironment. 
CXCR2 can induce the expression of matrix metalloproteinase 9 (MMP9) and vascular 
endothelial growth factor (VEGF) to recruit neutrophils (Albini, Mirisola et al. 2008). This 
subsequently leads to endothelial cell invasion and blood vessel formation.  On the other 
hand, there are reports demonstrated that neutrophils accumulate in the lung prior to the 
arrival of metastatic cells in mouse models of breast cancer. Those tumor entrained 
neutrophils (TENs) inhibit metastatic seeding in the lungs by generating H2O2. TENs are 
present in the peripheral blood of breast cancer patients prior to surgical resection but not in 
healthy individuals. Thus, whereas tumor-secreted factors contribute to tumor progression 
at the primary site, they concomitantly induce a neutrophil-mediated inhibitory process at 
the metastatic site. These neutrophils acquire a cytotoxic phenotype and provide anti-
metastatic protection by eliminating disseminated tumor cells. Although the neutrophils are 
eventually outcompeted by continued influx of metastatic cells, infusion of exogenous 
neutrophils effectively blocks metastasis and therefore represents a potential therapeutic 
strategy for management of micro-metastatic disease.(Granot, Henke et al. 2011) 
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Taken together, all of these infiltrated inflammatory cells secret different cytokines, 
chemokines, and other factors to influence the tumor cell migration and invasion and 
contribute to inflammation-mediated metastasis. 
4.4 Cytokines 
TNF-ǂ, a key inflammatory cytokine, plays a central role in tumor progression. Constitutive 
expression of TNF-ǂ from the tumor microenvironment is a characteristic of many 
malignant tumors and its presence is often associated with poor prognosis. Several lines of 
evidence point to the tumor-promoting effects of TNF-ǂ in inflammation-driven 
tumorigenesis. First, overexpression of TNF-ǂ confers migratory and invasive properties of 
many tumor cell lines (Rosen, Goldberg et al. 1991). Second, TNF-ǂ and TNF-ǂ receptor 1 
(TNFR1) knock-out mice are resistant to chemical-induced-carcinogenesis in skin and liver 
metastasis in an experimental colon cancer model (Knight, Yeoh et al. 2000; Arnott, Scott et 
al. 2004). Third, various tumor-promoting effects of TNF-ǂ are further confirmed in 
enhancing tumor cell motility, activating oncogenic pathways, and triggering EMT. TNF-ǂ 
can also promote breast cancer cell migration through up-regulating LOX (Liang, Zhang et 
al. 2007). Endogenous TNFǂ contributes to the growth and invasiveness of primary 
pancreatic ductal adenocarcinoma, and anti-TNFǂ inhibit metastasis of these tumors 
(Egberts, Cloosters et al. 2008). Using RNA interference technology, Kulbe et al 
demonstrated that tumor growth and dissemination were significantly inhibited when 
TNFǂ production was blocked (Kulbe, Thompson et al. 2007). In addition, TNF-ǂ can up-
regulate SELECTIN and VCAM1 on endothelial cells that promote tumor cell adhesion and 
migration (Mannel, Orosz et al. 1994; Stoelcker, Hafner et al. 1995). Furthermore, TNF-ǂ 
enhances the invasive property of cancer cells by inducing EMT through Snail or 
ZEB1/ZEB2 (Chua, Bhat-Nakshatri et al. 2007; Chuang, Sun et al. 2008). In our recent study, 
we found that inflammatory cytokine TNF-ǂ is the major signal to induce Snail stabilization 
and EMT induction (Wu, Deng et al. 2009). We showed that TNF-ǂ greatly enhanced the 
migration and invasion of tumor cells by inducing EMT program through NF-κB-mediated 
Snail stabilization. Knockdown of Snail expression not only inhibits TNF-ǂ-induced cancer 
cell migration and invasion in vitro but also suppresses LPS-mediated metastasis in vivo. 
Furthermore, knockdown of Snail expression not only blocks metastasis that is intrinsic to 
the metastatic breast cancer cells but also greatly suppresses inflammation-accelerated 
metastasis. Collectively, our study indicates that Snail stabilization and EMT induction 
mediated by the inflammatory cytokine TNF-ǂ are critical for metastasis. Our study 
provides a plausible molecular mechanism for tumor cell dissemination and invasion at the 
tumor invasive front.  
In fact, under hypoxic and inflammatory conditions, the tumor microenvironment generates 
and sustains a tumor-promoting cytokine network for facilitating tumor growth and 
metastasis. For example, the production of TGF-ǃ from myeloid cells, mesenchymal cells, 
and cancer cells is significantly enhanced in a hypoxic or inflammatory state. TGF-ǃ is a 
multifunctional growth factor with a complicated dual role in tumorigenesis(Leivonen and 
Kahari 2007). At the early stages of tumor formation, TGF-ǃ acts as a tumor suppressor by 
inhibiting proliferation and inducing apoptosis of tumor cells. At the later stages of 
tumorigenesis, TGF-ǃ functions as a tumor promoter by increasing tumor growth, survival, 
motility, and invasion. TGF-ǃ has also been shown to induce EMT in normal mammary 
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epithelial cells and breast cancer cell lines (Miettinen, Ebner et al. 1994) (Forrester, Chytil et 
al. 2005). As we mentioned in part-2.5 (Molecular regulation of EMT), TGF-ǃ plays an 
important role in the process of EMT. 
IL-6 is another important inflammatory cytokine linking inflammation and cancer. IL-6 
transmits its signal through a common signaling receptor, gp130, expressed in many cell 
types. IL-6 binds to the sIL-6R receptor (gp80, present either on the cell surface or in 
solution), which then induces dimerization of gp130 chains, resulting in activation of the 
associated Janus kinases (JAKs). JAKs phosphorylate gp130, leading to the recruitment and 
activation of the STAT3 and STAT1 transcription factors, as well as other molecules (SHP2, 
Ras-MAPK, and PI3K) (Mumm and Oft 2008). The role of IL-6 in accelerating tumorigenesis 
is becoming clear as exogenous administration of IL-6 to mice during tumor initiation 
results in an increase in tumor burden and multiplicity (Grivennikov, Karin et al. 2009). IL-6 
also enhances tumor proliferation in tumor-initiating intestinal epithelial cells (IECs) 
through NF-κB-IL-6-STAT3 cascade (Bollrath, Phesse et al. 2009; Bromberg and Wang 2009; 
Grivennikov, Karin et al. 2009). IL-6 can also act as an inducer of EMT in breast cancer cells. 
Ectopic expression of IL-6 in breast adenocarcinoma cells exhibits an EMT phenotype 
characterized by suppressing E-cadherin expression and inducting vimentin, N-cadherin, 
Snail and Twist (Sullivan, Sasser et al. 2009). In addition, IL-6 also synergizes with EGF in 
inducing EMT through the activation JNK2/STAT3 in ovarian carcinomas (Colomiere, 
Ward et al. 2009). 
The interleukin-1 (IL-1) also promotes inflammatory processes and augments metastasis. 
There are two forms of IL-1 protein, IL-1ǂ and IL-1ǃ, and one antagonistic protein IL-1 
receptor antagonist (IL-1ra). IL-1ǃ is active solely in its secreted form, whereas IL-1ǂ is 
active mainly as an intracellular precursor. IL-1 is abundant at tumor sites, where it affects 
the process of carcinogenesis, tumor growth and invasiveness, and the patterns of tumor-
host interactions (Apte, Krelin et al. 2006). Genetic ablation of IL-1ǃ in mice results in the 
absence of metastatic tumors in vivo (Voronov, Shouval et al. 2003). Liver metastasis can be 
almost completely inhibited in mice with deletion of the interleukin-1ǃ converting enzyme, 
which is required for the processing of IL-1ǃ (Vidal-Vanaclocha, Fantuzzi et al. 2000). IL-1ǃ 
also directly induces uPA expression and NF-κB activation, which results in the migration of 
A549 cells (Cheng, Hsieh et al. 2009). 
Together with chemotaxis, chemokines, a family of inducible chemo-attractant cytokines 
that regulate the chemotaxis of tumor cells and other cell types, are thought to be involved 
in every crucial step of tumor cell dissemination (Roussos, Condeelis et al. 2011). 
Chemotaxis of carcinoma cells and tumor-associated inflammatory and stromal cells is 
mediated by chemokines, chemokine receptors, growth factors and growth factor receptors. 
Chemotaxis helps to shape the tumor microenvironment. Directional migration to a 
chemokine source is evident both in vitro and in vivo for most cells of the tumor 
microenvironment. The most common chemokine receptor detected in cancer cells is 
CXCR4; another common one is CCR7 (Muller, Homey et al. 2001; Lazennec and Richmond 
2010). In standard chemotaxis assays in vitro, CXCR4-positive cancer cells can migrate in a 
directional manner toward CXCL12, whereas CCR7-expressing cancer cells can migrate 
towards CCL21 (Kodama, Hasengaowa et al. 2007; Pitkin, Luangdilok et al. 2007). Recently, 
it has been reported that the recruitment of inflammatory monocytes, which express CCR2, 
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is dependent on CCL2 synthesized by both the tumor and the stroma, facilitating breast-
tumor metastasis; the same is true for the subsequent recruitment of metastasis-associated 
macrophages and their interaction with metastasizing tumor cells (Qian, Li et al. 2011). 
5. Summary 
Every year about 500,000 people in the United States die as a result of cancer, among which 
90% exhibit systemic disease with metastasis. That’s why it is so important to understand 
the mechanism behind EMT and metastasis. Based on thousands of studies in this field in 
recent years, significant progress has been made regarding our understanding of EMT and 
metastasis, which point out that EMT is the most critical mechanism implicated in tumor 
metastasis and recurrence. It is now quite clearly that solid tumors are not simply clones of 
cancer cells. A variety of stromal cells in the surrounding environment are recruited to 
tumors, which including mesenchymal supporting cells (e.g. fibroblasts), cells of the 
vascular system, and cells from immune system, such as TAMs, Treg, MDSC, Neutrophils 
and so on. The dynamic interaction which exists between cancer cells and the inflammatory 
microenvironment not only enhances growth of the primary cancer but also facilitates its 
metastatic dissemination to distant organs. There are many evidences show that the 
induction of EMT is dependent on the signals that cells received from their 
microenvironment, and the crosstalk between inflammation and metastasis has an un-
replaceable role in each step for the successful establishment of a metastatic tumor (Fig. 2). 
 
Fig. 2. Tumor Inflammatory Microenvironment in EMT and Metastasis. 
Understanding how inflammatory microenvironment is maintained and how it contributes 
to the tumor progression and metastasis will be crucial for understanding tumor biology as 
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well as the development of new effective cancer prevention and therapy. Hopefully, with 
recent research illuminating the involvement of infiltrated inflammatory cells and many 
kinds of cytokines in tumor progression and EMT/Metastasis, a more comprehensive view 
of how cancer cells spreads to different organs in a specific manner will emerge in the near 
future. However, we have to realize that several challenges still need to be addressed about 
how to translate these basic findings into clinical practice and find novel treatment strategies 
targeting the inflammatory microenvironment which could efficiently kill both primary and 
metastatic tumor cells. 
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